A comprehensive review of interventions in the NOD mouse and implications for translation

被引:230
作者
Shoda, LKM
Young, DL
Ramanujan, S
Whiting, CC
Atkinson, MA
Bluestone, JA
Eisenbarth, GS
Mathis, D
Rossini, AA
Campbell, SE
Kahn, R
Kreuwel, HT
机构
[1] Entelos Inc, Foster City, CA 94404 USA
[2] Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA
[3] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA
[4] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Med, Joslin Diabet Ctr,Sect Immunol & Immunogenet, Boston, MA 02215 USA
[6] Univ Massachusetts, Sch Med, Diabet Div, Worcester, MA 01605 USA
[7] Amer Diabet Assoc, Alexandria, VA 22311 USA
关键词
D O I
10.1016/j.immuni.2005.08.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Type 1 diabetes (T1D) animal models such as the non-obese diabetic (NOD) mouse have improved our understanding of disease pathophysiology, but many candidate therapeutics identified therein have failed to prevent/cure human disease. We have performed a comprehensive evaluation of disease-modifying agents tested in the NOD mouse based on treatment timing, duration, study length, and efficacy. Interestingly, some popular tenets regarding NOD interventions were not confirmed: all treatments do not prevent disease, treatment dose and timing strongly influence efficacy, and several therapies have successfully treated overtly diabetic mice. The analysis provides a unique perspective on NOD interventions and suggests that the response of this model to therapeutic interventions can be a useful predictor of the human response as long as careful consideration is given to treatment dose, timing, and protocols; more thorough investigation of these parameters should improve clinical translation.
引用
收藏
页码:115 / 126
页数:12
相关论文
共 114 条
[1]   CD4(+) BETA-ISLET CELL-REACTIVE T-CELL CLONES THAT SUPPRESS AUTOIMMUNE DIABETES IN NONOBESE DIABETIC MICE [J].
AKHTAR, I ;
GOLD, JP ;
PAN, LY ;
FERRARA, JLM ;
YANG, XD ;
KIM, JI ;
TAN, KN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :87-97
[2]   The NOD mouse: A model of immune dysregulation [J].
Anderson, MS ;
Bluestone, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :447-485
[3]  
[Anonymous], 2004, National diabetes fact sheet
[4]   The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].
Ansari, MJI ;
Salama, AD ;
Chitnis, T ;
Smith, RN ;
Yagita, H ;
Akiba, H ;
Yamazaki, T ;
Azuma, M ;
Iwai, H ;
Khoury, SJ ;
Auchincloss, H ;
Sayegh, MH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69
[5]   INSULITIS AND DIABETES IN NOD MICE REDUCED BY PROPHYLACTIC INSULIN THERAPY [J].
ATKINSON, MA ;
MACLAREN, NK ;
LUCHETTA, R .
DIABETES, 1990, 39 (08) :933-937
[6]  
Bachmair L., 2001, HDB AUTOMATED REASON, VI, P19, DOI DOI 10.1016/B978-044450813-3/50004-7
[7]  
BAEDER WL, 1992, CLIN EXP IMMUNOL, V89, P174
[8]  
Balasa B, 1997, J IMMUNOL, V159, P4620
[9]   Standardizing experiments with NOD mice [J].
Beales, PE ;
Delovitch, TL ;
Signore, A ;
Pozzilli, P .
AUTOIMMUNITY, 1996, 24 (02) :127-129
[10]   TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes [J].
Belghith, M ;
Bluestone, JA ;
Barriot, S ;
Mégret, J ;
Bach, JF ;
Chatenoud, L .
NATURE MEDICINE, 2003, 9 (09) :1202-1208